The global cystic fibrosis therapeutics market grew at a CAGR of around 15% during 2014-2019. Cystic fibrosis (CF) is a rare and progressive genetic disorder that is characterized by an abnormal movement of sodium and chloride across the gastrointestinal and respiratory tracts. This disorder can cause the development of viscous secretions in the lungs, pancreas, intestines and liver. The management and treatment of CF involve physical therapy, gene therapy, physiotherapy and nutritional support. Along with this, gene therapy and medicinal drugs, such as pancreatic enzyme supplements, mucolytics, bronchodilators and cystic fibrosis transmembrane conductance regulator (CFTR) modulators are also used for targeting cellular interactomes and symptomatic improvement. These drugs can be administered to the patient orally or by inhalation.
The rising incidence of cystic fibrosis across the globe, along with improvements in the diagnostic technologies of the disorder, is one of the key factors driving the growth of the market. Furthermore, widespread adoption of cystic fibrosis transmembrane conductance (CFTR) modulators as a treatment alternative is also providing a boost to the market growth. CFTRs are configured to regulate the flow of water and chloride through cell linings of the lungs and other organs and correct the malfunctioning protein in the body. Additionally, various technological advancements, such as the development of personalized drug therapy, molecular prosthetics and innovative drugs with improved efficacy, are acting as another growth-inducing factor. Other factors, including rising healthcare expenditures, increasing health consciousness, and awareness regarding the available treatment options for cystic fibrosis, are projected to drive the market further. Looking forward, IMARC Group expects the market to continue to exhibit strong growth during 2020-2025.
Breakup by Drug Class:
Breakup by Drug Molecule Type:
Breakup by Route of Administration:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being AbbVie Inc., Alaxia, Alcresta Therapeutics Inc., Allergan, AstraZeneca, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Inc., etc.
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )
Drop us an email at